Document:

Yissum
Research Development Company

of
the Hebrew University of Jerusalem

Edmond
Safra Campus,

Givat
Ram, POB 39335

Jerusalem
91390

Israel

 

Re:
Extension of Agreement for rendering of Services

 

We
do hereby refer to the Agreement for the Rendering of Services dated as of June 20, 2005 ("Service Agreement")
and the License Agreement dated November 27, 2002, (the "License Agreement") by and between Yissum Research Development
Company 0f the Hebrew University of Jerusalem ('Yissum") and Morria Biopharmaceuticals ("the Company'').

Unless
the context otherwise requires, all capitalized terms used herein shall have the meaning ascribed to them in the Service Agreement.

The
Company docs hereby request that that Yissum performs the additional tasks and activities set forth on Appendix B hereto ("Additional
Services"). All of such Additional Services shall be included as Services under the Service Agreement, and shall be performed
in accordance with the timetable set forth on Appendix B hereto. In consideration, Morria shall pay to Yissum an additional amount,
of $30,000 (plus VAT) (the "Additional Service Fee") payable within seven days of the signing of this
Letter of Extension.

All
terms and conditions as set out in the Service Agreement shall apply mutatis mutandis in respect of the Additional Service
Fee and the Additional Services.

Your
signature on this copy of the document shall constitute your approval and agreement to all that is written herein.

 

Yours
sincerely,

 

	MORRIA BIOPHARMACEUTICALS PLC.	 	 
	 	 	 
	/s/ YUVAL COHEN	 	 	 
	 	 	 
	By: Yuval Cohen	 	Date: June 19, 2006
	 	 	 
	Title: CEO	 	 
	 	 	 
	 	 	 	 
	We hereby agree and approve: 	 	 
	/s/ ELENA CANETTI	 	 
	 	 	 	 
	 	 	 
	By: Elena Canetti, VP Scientific Services	 	Date: June 4, 2006
	Yissum	 	 
	 	 	 
	/s/ NAVA SWERSKY SOFER	 	 
	By: Nava Swersky Sofer, CEO	 	 
	Yissum	 	Date:  

 

    	1Yissum
Research Development Company

 

of
the Hebrew University of Jerusalem

 

Edmond
Safra Campus,

 

Givat
Ram, POB 39135

 

Jerusalem
91390

 

Israel

 

Re:
Second Extension of Agreement for rendering of Services

 

We
do hereby refer to the Agreement for the Rendering of Services dated as of June 20, 2005 (the "Service Agreement")
and the extension thereto dated as of June 2006 ("Extension of Agreement for Rendering of Services") (jointly
with the Services Agreement, the "Extended Service Agreement") and the License Agreement dated November 27th,
2002 (the "License Agreement") all executed by and between Yissum Research Development Company of the Hebrew University
of Jerusalem ("Yissum") and Morria Biopharmaceuticals, Inc. (the "Company").

 

Unless
the context otherwise requires, all capitalized terms used herein shall have the meaning ascribed to them in the Service Agreement.

 

The
Company does hereby request that, further to Yissum tasks and services pursuant to the Extended Service Agreement, Yissum performs
the additional tasks and services set forth on Appendix A hereto (the "Additional Services"). All of such Additional
Services shall be included in the scope of the definition of Services under the Service Agreement, and shall be performed in accordance
with the timetable set forth on Appendix A hereto. In consideration, the Company shall pay Yissum an additional amount, of $ 40,500
(plus VAT) (the "Additional Service Fee") payable within seven days of the signing of this Letter of Extension.

 

All
terms and conditions as set out in the Service Agreement shall apply mutatis mutandis in respect of the Additional Service
Fee and the Additional Services as defined under this Second Extension of Agreement for Rendering of Services, including without
limitation, the extension of the right and license to the Company of the Service Agreement Results, such to include the Additional
Services (as defined herein).

 

Your
signature on this copy of the document shall constitute your approval and agreement to all that is written herein.

 

    	1

    	 

    

 

	Yours sincerely,	 	 
	 	 	 
	MORRIA BIOPHARMACEUTICALS PLC.	 	 
	/s/ YUVAL COHEN	 	 
	 	 	 	 
	By:
Yuval Cohen, Managing Director, Morria	 	 
	 	 	 
	We
hereby agree and approve:	 	 
	/s/ ELENA CANETTI	 	 
	 	 	 	 
	By: Elena Canetti, VP Scientific Services, Yissum	 	Date: December 19, 2006
	 	 	 
	/s/ NAVA SWERSKY SOFER	 	 
	 	 	 	 
	 	 	 
	 By: Nava Swersky Sofer, CEO, Yissum	 	Date: December 19, 2006 

  

    	2

    	 

    

 

APPENDIX
A

 

Research
Program for Morria Biopharmaceuticals Plc

 

Proposed
by Prof. Saul Yedgar of

the Hebrew University Medical School, Jerusalem

 

Aim:
Development of analytical methods for characterization of MFAIDs and their stability. 

 

Scope

 

		1.	Monitoring of HyPE temporal stability in different solvents,
including 0.lmM and 0.2 mM NaN03, PBS, Na Glutarate, NaCitrate, following filter-sterilization, and storing at room temperature
and 4°C, using

 

		A.	Visocisty (Ostwald capillary viscometers).

 

		B.	Dynamic light scattering (DSL), which will also be used for analyzing
the size distribution of HyPE population into multi-molecular organizations, and its changes during the storage period.

	 	 	 
		2.	Testing
                                                                                                                   of validation
                                                                                                                   methods for
                                                                                                                   HyPE concentration
                                                                                                                   in solutions:
	 	 	 
	 	 	HyPE
solutions, at a wide range of concentrations, will be prepared by the conventional method of dissolving weighted amounts in solvents,
using three analytical balances. The solutions will be subjected to determination by other physico-chemical methods, in order to
prepare corresponding standard curves.

Method to be examined:

Viscosity.

 

Colorimetric
determination of Optical density (spectrophotometry), Dynamic light Scattering.

 

Density
determination by Sound velocity or pycnometry, Elemental analysis.

  

		3.	Testing of MFAID candidates for their potential in treating inflammatory
conditions (inter alia IBD Alzheimer, ALS, cystic fibrosis, arthritis, cancer, stenosis/restenosis, atherosclerosis, Malaria).

 

Duration:
6 months with report to Morria upon request and at the end of period.

Budget:
$40,500 total (including overhead).

 

    	3Yissum
Research Development Company

of
the Hebrew University of Jerusalem

Edmond
Safra Campus,

Givat
Ram, POB 39135

Jerusalem
91390

Israel

 

Re:
Third Extension of Agreement for rendering of Services

 

We
do hereby refer to the Agreement for the Rendering of Services dated as of June 20, 2005 (the "Service Agreement")
and the extension thereto dated as of June, 20 2006 ("Extension of Agreement for Rendering of Services") (jointly
with the Services Agreement, the "Extended Service Agreement") and the second extension thereto dated as of December
19, 2006 ("Second Extension of Agreement for Rendering of Services") and the License Agreement dated November
27th, 2002 (the "License Agreement") all executed by and between Yissum Research Development Company
of the Hebrew University of Jerusalem ("Yissum") and Morria Biopharmaceuticals, Inc. (the "Company").

 

Unless
the context otherwise requires, all capitalized terms used herein shall have the meaning ascribed to them in the Service Agreement.

 

The
Company does hereby request that, further to Yissum tasks and services pursuant to the Extended Service Agreement and the Second
Extended Service Agreement, and fully completed and performed by Yissum, Yissum performs the additional tasks and services set
forth on Appendix A hereto (the "Additional Services"). All of such Additional Services shall be included in the
scope of the definition of Services under the Service Agreement, and shall be performed in accordance with the timetable set forth
on Appendix A hereto. In consideration, the Company shall pay Yissum an additional amount, of $ 90,000 (plus VAT) (the "Additional
Service Fee") payable in quarterly payments from the signing of this Letter of Extension and according to the following
schedule:

i. $
22,500 plus VAT within fourteen (14) days of signing this Agreement.

ii. $
22,500 plus VAT on September 15, 2007.

iii. $
22,500 plus VAT on December 18, 2007 and

iv. $
22,500 plus VAT on March 15, 2008.

 

All
terms and conditions as set out in the Service Agreement shall apply mutatis mutandis in respect of the Additional Service
Fee and the Additional Services as defined under this Third Extension of Agreement for Rendering of Services, including without
limitation, the extension of the right and license to the Company of the Service Agreement Results, such to include the Additional
Services (as defined herein).

 

    	1

    	 

    

 

Your
signature on this copy of the document shall constitute your approval and agreement to all that is written herein.

 

Yours
sincerely,

 

	MORRIA BIOPHARMACEUTICALS PLC.	 
	 	 	 
	/s/ YUVAL COHEN	 	 
	 	 	 
	By: Yuval Cohen	 	Date: June 10, 2007
	 	 	 
	Title: Managing Director, Morria	 	 
	 	 	 
	/YISSUM STAMP/	 	 
	 	 	 
	We hereby agree and approve:		 
	 	 	 
	/s/ ELENA CANETTI	 	 
	 	 	 
	By: Elena Canetti	 	Date: June 10, 2007
	Title: VP Scientific Services Yissum	 	 
	 	 	 
	/s/ NAVA SWERSKY SOFER	 	 
	 	 	 
	By: Nava Swersky Sofer	 	Date: June 17, 2007
	Title: CEO Yissum	 	 

 

 

    	2

    	 

    

 

APPENDIX
A

 

Research
Program for Morria Biopharmaceuticals Plc

 

Proposed by Prof.
Saul Yedgar of the Dept of Biochemistry, Hebrew University Medical School, Jerusalem

 

Aim

 

Exploring
mechanisms of inflammatory processes and the therapeutic potential of MFAIDs in in vitro and in vivo models.

 

Scope

 

		1.	Exploration of inflammatory mechanisms and their control
in in vitro and in vivo experimental systems.

 

		2.	Testing of MFAID candidates for their potential in treating inflammatory/allergic
conditions: IBD, cancer, asthma, skin inflammation, eye inflammation, wound healing, viral infections and CNS.

 

		3.	Continuing the chemical characterization and optimization of MFAIDs.

 

		4.	Setting up new in vivo and in vitro models for testing
MFAIDs on inflammatory/allergic diseases.

 

Outcomes

 

		·	Data on efficacy of various MFAIDs in the above-mentioned disease
fields.

		·	Optimization of selected MFAID synthesis,

 

Research
Period: 12 months.

 

Budget:
up to $90,000 total (including overhead) to be paid in quarterly payments.

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]